News
ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively To Health Care Practitioners
23 Jul 24
Biotech, News, General
ChromaDex To Ship Pharmaceutical-Grade Intravenous and Injectable Niagen At Wellness Clinics In August
16 Jul 24
Biotech, News, General
HC Wainwright & Co. Reiterates Buy on ChromaDex, Maintains $6 Price Target
15 Jul 24
News, Price Target, Reiteration, Analyst Ratings
Roth MKM Maintains Buy on ChromaDex, Maintains $6 Price Target
12 Jun 24
News, Price Target, Analyst Ratings
Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
7 Jun 24
News, Intraday Update, Markets, Movers, Trading Ideas
ChromaDex Gets Orphan Designation Status From FDA For Nicotinamide Riboside Chloride For Treatment Of Ataxia Telangiectasia
3 Jun 24
Biotech, News, FDA, General
HC Wainwright & Co. Reiterates Buy on ChromaDex, Maintains $6 Price Target
9 May 24
News, Price Target, Reiteration, Analyst Ratings
12 Health Care Stocks Moving In Wednesday's After-Market Session
8 May 24
Movers
ChromaDex Q1 2024 Adj EPS $(0.01) Beats $(0.02) Estimate, Sales $22.200M Miss $23.970M Estimate
8 May 24
Earnings, Earnings Beats, Earnings Misses, News
Press releases
ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
24 Jul 24
Press Releases
ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)
23 Jul 24
Press Releases
ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel
22 Jul 24
Press Releases
ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August
16 Jul 24
Press Releases
ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
13 Jun 24
Press Releases
ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)
7 Jun 24
Press Releases
ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Tuesday, June 11, 2024
4 Jun 24
Press Releases
ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
23 May 24
Press Releases
ChromaDex's Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award
22 May 24
Press Releases
ChromaDex Corporation Reports First Quarter 2024 Financial Results
8 May 24
Press Releases
ChromaDex's NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement
30 Apr 24
Press Releases